Paul Freeman
Head of Upstream Process Science & Vector Core Scientist Affinia Therapeutics
Seminars
Thursday 26th February 2026
Re-Engineering AAV9 to Minimize Off Target Effects & Improve Efficacy
9:30 am
- Discussing techniques to maintain process robustness across diverse capsids and payloads
- Highlighting Affinia’s use of single-use clarification, affinity purification and UAC to achieve full capsid enrichment to ensure batch consistency and regulatory confidence
- Presenting lessons from the transfer of AFTX-201 high yield process to a CDMO partner, including reproducibility of yield and capsid quality across sites
